Full-Time

Contract Specialist

Legal

Posted on 9/11/2025

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

No salary listed

Plano, TX, USA

In Person

Category
Legal & Compliance (2)
,
Required Skills
Oracle
Requirements
  • Minimum Education: B.A degree required / Paralegal certification a plus but not required.
  • Minimum Experience: 10+ years’ work experience as a corporate contracts specialist.
  • Experience in an in-house/corporate law department; paralegal experience in corporate law section of a law firm is a plus.
  • Ability to interact with people at all levels of the corporate structure, prioritize and handle numerous competing demands in a high-volume, fast-paced working environment.
  • Ability to communicate effectively and work collaboratively with a variety of stakeholders, including outside attorneys, senior management, and business associates.
  • Ability to anticipate support needs of attorneys across a variety of matters.
  • Self-motivated and proven ability to work effectively in independent settings.
  • Ability to identify and resolve or escalate issues in a timely manner.
  • Ability to analyze, solve problems, and adapt to constantly changing priorities and organizational and operational needs.
  • Ability to use good judgment, maintain confidential information, be discreet and highly trustworthy, and demonstrate ethical conduct.
  • Excellent written and verbal communication, time-management, prioritization, and organizational skills with close attention to detail.
  • Ability to learn new skills and utilize new technology.
  • Positive attitude and a desire to be part of a strong, supportive team.
  • Strong understanding of contract drafting and understanding of commercial legal language and provisions.
  • Highly proficient in Microsoft Office Suite (Word, Excel, PowerPoint, SharePoint)
  • Familiarity with electronic billing systems.
Responsibilities
  • Adhere to Integer’s Values and all safety, environmental, security and quality requirements including, but not limited to: Quality Management Systems (QMS), Safety, Environmental and Security Management Systems, U.S. Food and Drug Administration (FDA) regulations, Company policies and operating procedures, and other regulatory requirements.
  • Draft, review and participate in the negotiation of a wide variety of contracts (both customer [sell-side] and vendor contracts [buy-side], with an emphasis sell-side), such as: supply contracts, purchase contracts, distribution agreements, development contracts, consulting agreements, real estate leases and related documents, and amendments to all of the foregoing; IT agreements (including SAAS, hardware, IT services & SOWs, license agreements); prepare and route contracts for approval and execution.
  • Work with functional teams including Sales, Legal, Quality, Operations, Finance, etc. to align functional needs with specific contracts as necessary.
  • Draft and negotiate non-disclosure/confidentiality agreements (both company and counter-party templates); prepare and route for execution; maintenance of document storage in Oracle.
  • Ensure that signed contracts are communicated to relevant parties to provide contract visibility and awareness.
  • Manage contract workflows and oversee tracking. Work cross functionally with other contract management specialists, business clients and corporate procurement teams.
  • Manage Legal Department Knowledge Management Systems: Create, update and maintain contract-related resources on legal department intranet site, template warehouse (including process forms and contracts), playbooks, and other resources to meet commercial team, legal team and organization objectives.
  • Work closely with IT with respect to strategic planning and ongoing system administration to ensure departmental use of contract-related technology for efficient and effective operations; manage relationships with internal and external providers of contract-related technology services and oversee procurement and implementation of contract-related software and hardware as appropriate.
  • Analyze existing contract processes, create recommendations for and implement process improvements. Oversee company’s relationship with its external commercial real estate broker, maintain real estate records to ensure accuracy, monitor deadlines monthly, liaise with other internal business functions as necessary.
  • Provide support on mergers and acquisitions as needed.
  • Keep apprised of legal developments that impact the Company’s contract obligations, negotiations and drafting of agreements.
  • Participate in department-wide strategic initiatives.
  • Perform other duties and special projects as assigned.
Desired Qualifications
  • Paralegal certification a plus but not required.
  • Experience in an in-house/corporate law department; paralegal experience in corporate law section of a law firm is a plus.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Simplify Jobs

Simplify's Take

What believers are saying

  • Board initiated strategic review on April 30, 2026, exploring sale options.
  • Irenic Capital acquired $99M stake in Q4 2025 as top holding.
  • $200M share repurchase authorization signals management confidence in valuation.

What critics are saying

  • Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
  • Three new products cause 3-4% headwind, slashing H2 2026 margins.
  • Irenic activism forces sale at depressed valuation below $93 target in 12 months.

What makes Integer Holdings Corporation unique

  • Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
  • Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
  • Robust pipeline targets above-market growth by 200 basis points in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.

Yahoo Finance
Feb 19th, 2026
Integer faces 2026 headwinds from delayed product launches despite $200M buyback and robust pipeline

Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.

INACTIVE